Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus

被引:7
|
作者
Gomez-Gutierrez, Jorge G. [1 ]
Rao, Xiao-Mei [1 ,2 ]
Zhou, Heshan Sam [1 ,2 ]
McMasters, Kelly M. [1 ,2 ]
机构
[1] Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA
[2] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA
关键词
Lung; Cancer; Virotherapy; E2Ftr; Apoptosis; In vivo; CONDITIONALLY REPLICATING ADENOVIRUS; EFFICIENTLY INDUCES APOPTOSIS; TRANSCRIPTION FACTOR; IN-VIVO; GENE-TRANSFER; MELANOMA-CELLS; CYCLIN-E; DEFECTIVE ADENOVIRUS; LUNG-CANCER; S-PHASE;
D O I
10.1016/j.virol.2012.09.003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Adenovirus-mediated gene transfer into a tumor mass can be improved by combining it with conditionally-replicating adenovirus (CRAd) when both vectors co-infect the same cancer cell. We investigated the efficiency of enhancing transgene expression and effectiveness of cancer killing of two advenoviruses (Ads), one expressing E2F-1 (AdE2F-1) and another expressing a truncated form of E2F-1 that lacks the transactivation domain (AdE2Ftr), when combined with oncolytic Adhz60. We found that AdE2F-1 with Adhz60 actually decreased E2F-1 expression and viral replication through a mechanism apparently involving repression of the cyclin-E promoter and decreased expression of early and late structural proteins necessary for viral replication. In contrast, AdE2Ftr with Adhz60 resulted in increased E2Ftr expression, AdE2Ftr replication, and cancer cell death both in vitro and in vivo. These results indicate that AdE2Ftr coupled with a CRAd enhances AdE2Ftr-mediated cancer cell death. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:538 / 547
页数:10
相关论文
共 50 条
  • [21] Colon cancer metastasis - Is E2F-1 a driving force?
    Enders, GH
    CANCER BIOLOGY & THERAPY, 2004, 3 (04) : 400 - 401
  • [22] Significance of E2F-1 overexpression in epithelial ovarian cancer
    Suh, D. S.
    Yoov, M. S.
    Choi, K. U.
    Kim, J. Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (03) : 492 - 498
  • [23] Induction of the cellular E2F-1 promoter by the adenovirus E4-6/7 protein
    Schaley, J
    O'Connor, RJ
    Taylor, LJ
    Bar-Sagi, D
    Hearing, P
    JOURNAL OF VIROLOGY, 2000, 74 (05) : 2084 - 2093
  • [24] E2F-1 induced apoptosis
    A. C. Phillips
    K. H. Vousden
    Apoptosis, 2001, 6 : 173 - 182
  • [25] E2F-1 induced apoptosis
    Phillips, AC
    Vousden, KH
    APOPTOSIS, 2001, 6 (03) : 173 - 182
  • [26] Role of E2F-1 in chemosensitivity
    Banerjee, D
    Schnieders, B
    Fu, JZ
    Adhikari, D
    Zhao, SC
    Bertino, JR
    CANCER RESEARCH, 1998, 58 (19) : 4292 - 4296
  • [27] Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin
    Yoon, AR
    Kim, JH
    Lee, YS
    Kim, H
    Yoo, JY
    Sohn, JH
    Park, BW
    Yun, CO
    HUMAN GENE THERAPY, 2006, 17 (04) : 379 - 390
  • [28] Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin
    Yoon, A-Rum
    Lee, Young-Sook
    Yoo, Ji-Young
    Kim, Hoguen
    Kim, Jinsun
    Ahn, Joong Bae
    Kim, Joo-Hang
    Yun, Chae-Ok
    MOLECULAR THERAPY, 2006, 13 : S324 - S325
  • [29] Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Δ24RGD
    Majem, M.
    Cascallo, M.
    Bayo-Puxan, N.
    Mesia, R.
    Germa, J. R.
    Alemany, R.
    CANCER GENE THERAPY, 2006, 13 (07) : 696 - 705
  • [30] An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors:: Dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy
    Jakubczak, JL
    Ryan, P
    Gorziglia, M
    Clarke, L
    Hawkins, LK
    Hay, C
    Huang, Y
    Kaloss, M
    Marinov, A
    Phipps, S
    Pinkstaff, A
    Shirley, P
    Skripchenko, Y
    Stewart, D
    Forry-Schaudies, S
    Hallenbeck, PL
    CANCER RESEARCH, 2003, 63 (07) : 1490 - 1499